Melatonin, produced in the pineal gland, is an endogenous regulator of circadian rhythms. It acts through the melatonin receptors (MT1 and MT2) and has been shown to have anti-depressant activity in experimental models of clinical depression. Agomelatine is a metabolically stable analog of melatonin that displays agonist activity for MT1 and MT2 binding with nanomolar affinity.1 However, unlike melatonin, agomelatine is a competitive antagonist of human and porcine serotonin (5-HT2C) receptors (pKi = 6.2 and 6.4, respectively) as well as human 5-HT2B receptors (pKi = 6.6).2 Agomelatine abolishes 5-HT2C agonist effects both in cells and in vivo. It also dose dependently increases extracellular levels of noradrenaline and dopamine in frontal cortex of freely moving rats.2
1
Yous, S., Andrieux, J., Howell, H.E., et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem35(8)1484-1486(1992).
2
Millan, M.J., Gobert, A., Lejeune, F., et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther306(3)954-964(2003).
Room temperature
in continental US; may vary elsewhere
SMILES
Copy SMILES to clipboard
COc1ccc2cccc(CCNC(=O)C)c2c1
Background Reading
Yous, S., Andrieux, J., Howell, H.E., et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem35(8)1484-1486(1992).
Millan, M.J., Gobert, A., Lejeune, F., et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther306(3)954-964(2003).
Agomelatine is available in the following screening
library: